JAISIM SHAH
CIK 1242133 · See Remarks · last filed 2024-12-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$53.2K
Companies
3
Total Filings
29
Lifetime Open-Market Net
-$670.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCLXW | See Remarks | 295,215 | $0.18 | $53.2K | $197.2K | 8 | 2024-12-18 |
| Sorrento Therapeutics, Inc. (SRNE) Delisted | Director | 178,075 | $0.00 | $89 | $399.7K | 16 | 2021-08-30 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | SVP, Mktg & Bus. Affairs | 15,812 | — | — | -$1.27M | 5 | 2008-04-30 |
Recent Filings · Page 3 of 3
29 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-09-22 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-11-26 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Buy (P) | +1,000 | $8.7K | EDGAR |
| 2013-11-20 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Buy (P) | +1,000 | $9.0K | EDGAR |
| 2013-10-31 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-04-30 | PDL BIOPHARMA, INC. (PDLI) Delisted | Exer (M) | +1,251 | $10.7K | EDGAR |
| 2007-08-17 | PDL BIOPHARMA, INC. (PDLI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-04-30 | PDL BIOPHARMA, INC. (PDLI) Delisted | Mixed | +260 | -$168.4K | EDGAR |
| 2007-04-24 | PDL BIOPHARMA, INC. (PDLI) Delisted | Mixed | — | -$160.2K | EDGAR |
| 2007-04-17 | PDL BIOPHARMA, INC. (PDLI) Delisted | Mixed | — | -$293.8K | EDGAR |
Showing 21–29 of 29
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.